


ATC codes: **L01XA02**

Indication	Other specified carcinomas of ovary <span style="float: right;">ICD11 code: <b>2D23.0Y</b></span>
INN	Carboplatin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL
EML status history	First added in 2009 ( <b>TRS 958</b> ) Changed in 2015 ( <b>TRS 994</b> )
Sex	Female
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <b>about patents.</b> 

Tags

Cancer

Wikipedia

[Carboplatin](#) 

DrugBank

[Carboplatin](#) 

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, the listing for carboplatin on the EML for use in treatment protocols for epithelial ovarian cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for epithelial ovarian cancer is attached.

[Expert Committee report](#) 

